Japanese T@DM patients were enrolled in a prospective , randomized , open-label , blinded-end point study and received pioglitazone with or without other oral glucose-lowering drugs ( excluding another thiazolidinedione -LSB- TZD -RSB- ) ( n = @ ) or oral glucose-lowering drugs excluding TZD ( n = @ ) .